|
시장보고서
상품코드
1671061
세계의 중추신경계 치료제 시장 - 규모, 점유율, 동향, 산업 분석 보고서 : 질환별, 약제 클래스별, 유통 채널별, 지역별 예측(2025-2034년)Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Drug Class, Distribution Channel, and Region - Market Forecast, 2025-2034 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면 세계 중추 신경계 치료제 시장 규모는 2034년까지 3,812억 7,000만 달러에 달할 전망입니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
중추신경계(CNS) 치료제 시장은 알츠하이머병, 파킨슨병, 간질, 우울증 등 신경질환의 치료제와 치료법을 포함하며, 뇌와 척수의 건강과 기능 개선에 중점을 두고 있습니다.
중추신경계(CNS) 치료제 시장은 뇌종양, 신경교종 등의 CNS암 발생률 증가로 확대되고 있습니다. 진단 건수 증가로 효과적인 치료에 대한 수요가 높아지고 있습니다. 예를 들어 미국 뇌종양협회의 보고에 따르면 미국에서는 매년 9만 명이 원발성 뇌종양으로 진단되고 있으며, 증례 증가 경향을 반영하고 있습니다. 또한 고령자는 암의 원인이 되는 방사선의 영향을 받기 쉽기 때문에 고령화도 중추신경계 암 증가에 기여하고 있습니다.
중추 신경계(CNS) 치료제 시장의 성장을 견인하는 것은 건강 관리에 대한 정부 지출 증가입니다. 정부와 민간 부문 모두 건강 관리에 대한 투자를 늘리고 있으며, 그 결과 우울증, 불안 신경증, 알츠하이머 병 등 중추 신경계 질환에 대한 효과적인 치료법 개발에 더욱 주력하게 되었습니다. 예를 들어, 세계은행 그룹에 따르면, 2021년 건강 관리 지출은 전체 GDP의 10.3%를 차지합니다. 이러한 재정 지원은 연구와 기술 혁신을 촉진하고 비용 효율적인 치료법의 도입으로 이어지고 있습니다.
중추 신경계 치료제 시장은 신경 질환의 식별을 용이하게 하는 고급 진단 기술에 의해 성장하고 있습니다. 이러한 진보는 조기 및 정확한 진단으로 이어져 효과적인 치료에 대한 수요가 증가하게 됩니다.
중추 신경계 치료제 시장 보고서 하이라이트
의약품 등급별로, 주의력 결핍 다동성 장애(ADHD)와 수면장애의 유병률이 증가함에 따라 중추 신경 자극제 부문은 세계 시장에서 높은 CAGR을 기록하고 큰 성장이 예상됩니다.
유통채널별로 알츠하이머병이나 파킨슨병 등 신경퇴행성 질환에 의한 입원 환자 수 증가로 2024년에는 병원 약국 부문이 중추신경계 치료제 시장을 독점했습니다.
2024년 중추신경계 치료제 시장에서는 알츠하이머병의 유병률 상승으로 북미가 가장 큰 매출 점유율을 차지했습니다.
인도의 중추신경계 치료제 시장은 제약 업계의 성장에 의해 상당한 성장이 예상되고 있습니다.
시장의 세계 주요 기업으로는 Biogen, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Merck & Co., Inc., Astra Zeneca, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Inc.; and Pfizer Inc 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 중추신경계 치료제 시장 인사이트
- 시장 현황
- 중추신경계 치료제 시장 역학
- 성장 촉진요인과 기회
- 고령자 인구 증가가 시장의 성장을 견인
- 정신건강에 대한 투자 증가가 시장 규모를 밀어 올리고 있습니다.
- 억제요인과 과제
- 규제상의 장애물
- 성장 촉진요인과 기회
- PESTEL 분석
- 중추신경계 치료제 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 중추신경계 치료제 시장 : 질환별
- 주요 조사 결과
- 소개
- 신경혈관 질환
- 중추신경계 외상
- 정신 건강
- 신경퇴행성 질환
- 감염증
- 중추신경계암
- 기타
제6장 세계의 중추신경계 치료제 시장 : 약제 클래스별
- 주요 조사 결과
- 소개
- 마취약
- 항경련제
- 제토제
- 중추 신경 자극제
- 진통제
- 기타
제7장 세계의 중추신경계 치료제 시장 : 유통 채널별
- 주요 조사 결과
- 소개
- 병원 약국
- 소매 약국
- 기타
제8장 세계의 중추신경계 치료제 시장 : 지역
- 주요 조사 결과
- 소개
- 중추신경계 치료제 시장의 평가 : 지역, 2020-2034년
- 북미
- 북미 : 질병별, 2020-2034년
- 북미 : 약제 클래스별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽: 질병별, 2020-2034년
- 유럽 : 약제 클래스별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양: 질병별, 2020-2034년
- 아시아태평양: 약제 클래스별, 2020-2034년
- 아시아태평양: 유통 채널별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카: 질병별, 2020-2034년
- 중동 및 아프리카 : 약제 클래스별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카: 질병별, 2020-2034년
- 라틴아메리카 : 약제 클래스별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 프로파일
- Biogen
- Otsuka Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- Merck & Co., Inc.
- Astra Zeneca
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Johnson & Johnson, Inc.
- Pfizer Inc.
The global central nervous system therapeutics market size is expected to reach USD 381.27 billion by 2034, according to a new study by Polaris Market Research. The report "Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Drug Class, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The central nervous system (CNS) therapeutics market encompasses drugs and treatments for neurological disorders like Alzheimer's, Parkinson's, epilepsy, and depression, focusing on improving brain and spinal cord health and function.
The central nervous system (CNS) therapeutics market is expanding due to the growing incidence of CNS cancers, including brain tumors, gliomas, and other types. The increasing number of diagnoses is driving demand for effective treatments. For example, the American Brain Tumor Association reports that 90,000 people in the US are diagnosed with a primary brain tumor each year, reflecting a rising trend in cases. Additionally, the aging population is contributing to the increase in CNS cancer cases, as older adults are more vulnerable to cancer-causing radiation.
The central nervous system (CNS) therapeutics market growth is being driven by increased government spending on healthcare. Both governments and private sectors are investing more in healthcare, which has led to a stronger focus on developing effective treatments for CNS disorders such as depression, anxiety, and Alzheimer's disease. For example, healthcare expenditure in 2021 accounted for 10.3% of total GDP, according to the World Bank Group. This financial support has fostered research and innovation, resulting in the introduction of cost-effective therapies.
The central nervous system therapeutics market is growing due to advanced diagnostic technologies that make it easier to identify neurological disorders. These advancements lead to earlier and more accurate diagnoses and lead to an increased demand for effective treatments.
Central Nervous System Therapeutics Market Report Highlights
Based on drug class, the CNS stimulants segment is expected to experience significant growth with a high CAGR in the global market due to the rising prevalence of attention deficit hyperactivity (ADHD) and sleep disorders.
By distribution channel, the hospital pharmacies segment dominated the central nervous system therapeutics market in 2024 due to the rising number of hospital admissions for neurodegenerative diseases, such as Alzheimer's and Parkinson's.
In 2024, North America had the largest revenue share in the central nervous system therapeutics market due to the rising prevalence of Alzheimer's disease.
The central nervous system therapeutics market in India is projected for substantial growth, driven by the growth of the pharmaceutical industry.
A few of the global key market players are Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Astra Zeneca; Takeda Pharmaceutical Company Limited; Novartis AG; Teva Pharmaceutical Industries Ltd; Johnson & Johnson, Inc.; and Pfizer Inc.
Polaris market research has segmented the central nervous system therapeutics market report on the basis of disease, drug class, distribution channel, and region:
By Disease Outlook (Revenue - USD Billion, 2020-2034)
- § Neurovascular Diseases
- § CNS Trauma
- § Mental Health
- § Neurodegenerative Diseases
- § Alzheimer's Disease
- § Parkinson's Disease
- § Multiple Sclerosis
- § Huntington's Disease
- § Amyotrophic Lateral Sclerosis
- § Others
- § Infectious Diseases
- § CNS Cancer
- § Others
By Drug Class Outlook (Revenue - USD Billion, 2020-2034)
- § Anesthetics
- § Anticonvulsants
- § Antiemetics
- § CNS Stimulants
- § Pain Relievers
- § Others
By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)
- § Hospital Pharmacies
- § Retail Pharmacies
- § Others
By Regional Outlook (Revenue - USD Billion, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Central Nervous System Therapeutics Market Insights
- 4.1. Central Nervous System Therapeutics Market - Market Snapshot
- 4.2. Central Nervous System Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Geriatric Population is Driving Market Growth
- 4.2.1.2. Increase in Investment in Mental Health is Propelling Market Size
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory Hurdle
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Central Nervous System Therapeutics Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Central Nervous System Therapeutics Market, by Disease
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 5.3. Neurovascular Disease
- 5.3.1. Global Central Nervous System Therapeutics Market, by Neurovascular Disease, by Region, 2020-2034 (USD million)
- 5.4. CNS Trauma
- 5.4.1. Global Central Nervous System Therapeutics Market, by CNS Trauma, by Region, 2020-2034 (USD million)
- 5.5. Mental Health
- 5.5.1. Global Central Nervous System Therapeutics Market, by Mental Health, by Region, 2020-2034 (USD million)
- 5.6. Neurodegenerative Diseases
- 5.6.1. Global Central Nervous System Therapeutics Market, by Neurodegenerative Diseases, by Region, 2020-2034 (USD million)
- 5.6.2. Alzheimer's Disease
- 5.6.2.1. Global Central Nervous System Therapeutics Market, by Alzheimer's Disease, by Region, 2020-2034 (USD million)
- 5.6.3. Parkinsosn's Disease
- 5.6.3.1. Global Central Nervous System Therapeutics Market, by Parkinsosn's Disease, by Region, 2020-2034 (USD million)
- 5.6.4. Multiple Sclerosis
- 5.6.4.1. Global Central Nervous System Therapeutics Market, by Multiple Sclerosis, by Region, 2020-2034 (USD million)
- 5.6.5. Huntington's Disease
- 5.6.5.1. Global Central Nervous System Therapeutics Market, by Huntington's Disease, by Region, 2020-2034 (USD million)
- 5.6.6. Amytrophic Lateral Sclerosis
- 5.6.6.1. Global Central Nervous System Therapeutics Market, by Amytrophic Lateral Sclerosis, by Region, 2020-2034 (USD million)
- 5.6.7. Others
- 5.6.7.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)
- 5.7. Infectious Diseases
- 5.7.1. Global Central Nervous System Therapeutics Market, by Infectious Diseases, by Region, 2020-2034 (USD million)
- 5.8. CNS Cancer
- 5.8.1. Global Central Nervous System Therapeutics Market, by CNS Cancer, by Region, 2020-2034 (USD million)
- 5.9. Others
- 5.9.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)
6. Global Central Nervous System Therapeutics Market, by Drug Class
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 6.3. Anesthetics
- 6.3.1. Global Central Nervous System Therapeutics Market, by Anesthetics, by Region, 2020-2034 (USD million)
- 6.4. Anticonvulsants
- 6.4.1. Global Central Nervous System Therapeutics Market, by Anticonvulsants, by Region, 2020-2034 (USD million)
- 6.5. Antiemetics
- 6.5.1. Global Central Nervous System Therapeutics Market, by Antiemetics, by Region, 2020-2034 (USD million)
- 6.6. CNS Stimulants
- 6.6.1. Global Central Nervous System Therapeutics Market, by CNS Stimulants, by Region, 2020-2034 (USD million)
- 6.7. Pain Relievers
- 6.7.1. Global Central Nervous System Therapeutics Market, by Pain Relievers, by Region, 2020-2034 (USD million)
- 6.8. Others
- 6.8.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)
7. Global Central Nervous System Therapeutics Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Central Nervous System Therapeutics Market, by Hospital Pharmacies, by Region, 2020-2034 (USD million)
- 7.4. Retail Pharmacies
- 7.4.1. Global Central Nervous System Therapeutics Market, by Retail Pharmacies, by Region, 2020-2034 (USD million)
- 7.5. Others
- 7.5.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)
8. Global Central Nervous System Therapeutics Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Central Nervous System Therapeutics Market Assessment, By Geography, 2020-2034 (USD million)
- 8.3. Central Nervous System Therapeutics Market - North America
- 8.3.1. North America: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.3.2. North America: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.3.3. North America: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.3.4. Central Nervous System Therapeutics Market - U.S.
- 8.3.4.1. U.S.: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.3.4.2. U.S.: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.3.4.3. U.S.: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.3.5. Central Nervous System Therapeutics Market - Canada
- 8.3.5.1. Canada: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.3.5.2. Canada: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.3.5.3. Canada: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4. Central Nervous System Therapeutics Market - Europe
- 8.4.1. Europe: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.2. Europe: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.3. Europe: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.4. Central Nervous System Therapeutics Market - UK
- 8.4.4.1. UK: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.4.2. UK: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.4.3. UK: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.5. Central Nervous System Therapeutics Market - France
- 8.4.5.1. France: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.5.2. France: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.5.3. France: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.6. Central Nervous System Therapeutics Market - Germany
- 8.4.6.1. Germany: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.6.2. Germany: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.6.3. Germany: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.7. Central Nervous System Therapeutics Market - Italy
- 8.4.7.1. Italy: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.7.2. Italy: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.7.3. Italy: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.8. Central Nervous System Therapeutics Market - Spain
- 8.4.8.1. Spain: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.8.2. Spain: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.8.3. Spain: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.9. Central Nervous System Therapeutics Market - Netherlands
- 8.4.9.1. Netherlands: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.9.2. Netherlands: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.9.3. Netherlands: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.10. Central Nervous System Therapeutics Market - Russia
- 8.4.10.1. Russia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.10.2. Russia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.10.3. Russia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.11. Central Nervous System Therapeutics Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.11.2. Rest of Europe: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.11.3. Rest of Europe: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5. Central Nervous System Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.2. Asia Pacific: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.3. Asia Pacific: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.4. Central Nervous System Therapeutics Market - China
- 8.5.4.1. China: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.4.2. China: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.4.3. China: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.5. Central Nervous System Therapeutics Market - India
- 8.5.5.1. India: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.5.2. India: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.5.3. India: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.6. Central Nervous System Therapeutics Market - Malaysia
- 8.5.6.1. Malaysia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.6.2. Malaysia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.6.3. Malaysia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.7. Central Nervous System Therapeutics Market - Japan
- 8.5.7.1. Japan: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.7.2. Japan: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.7.3. Japan: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.8. Central Nervous System Therapeutics Market - Indonesia
- 8.5.8.1. Indonesia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.8.2. Indonesia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.8.3. Indonesia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.9. Central Nervous System Therapeutics Market - South Korea
- 8.5.9.1. South Korea: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.9.2. South Korea: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.9.3. South Korea: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.10. Central Nervous System Therapeutics Market - Australia
- 8.5.10.1. Australia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.10.2. Australia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.10.3. Australia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.11. Central Nervous System Therapeutics Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.11.2. Rest of Asia Pacific: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.11.3. Rest of Asia Pacific: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6. Central Nervous System Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.6.2. Middle East & Africa: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.6.3. Middle East & Africa: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.4. Central Nervous System Therapeutics Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.6.4.2. Saudi Arabia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.6.4.3. Saudi Arabia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.5. Central Nervous System Therapeutics Market - UAE
- 8.6.5.1. UAE: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.6.5.2. UAE: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.6.5.3. UAE: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.6. Central Nervous System Therapeutics Market - Israel
- 8.6.6.1. Israel: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.6.6.2. Israel: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.6.6.3. Israel: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.7. Central Nervous System Therapeutics Market - South Africa
- 8.6.7.1. South Africa: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.6.7.2. South Africa: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.6.7.3. South Africa: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.8. Central Nervous System Therapeutics Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.6.8.2. Rest of Middle East & Africa: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.6.8.3. Rest of Middle East & Africa: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7. Central Nervous System Therapeutics Market - Latin America
- 8.7.1. Latin America: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.7.2. Latin America: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.7.3. Latin America: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.4. Central Nervous System Therapeutics Market - Mexico
- 8.7.4.1. Mexico: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.7.4.2. Mexico: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.7.4.3. Mexico: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.5. Central Nervous System Therapeutics Market - Brazil
- 8.7.5.1. Brazil: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.7.5.2. Brazil: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.7.5.3. Brazil: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.6. Central Nervous System Therapeutics Market - Argentina
- 8.7.6.1. Argentina: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.7.6.2. Argentina: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.7.6.3. Argentina: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.7. Central Nervous System Therapeutics Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.7.7.2. Rest of Latin America: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.7.7.3. Rest of Latin America: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Biogen
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Otsuka Pharmaceutical Co., Ltd.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Eli Lilly and Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Merck & Co., Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Astra Zeneca
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Takeda Pharmaceutical Company Limited
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Teva Pharmaceutical Industries Ltd
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Johnson & Johnson, Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Pfizer Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
비교리스트